No Data
No Data
The actual controller of Remegen has accumulated a shareholding of 0.18 million shares in the company, involving 5.109 million yuan.
Remegen (09995) announced the progress of the controlling shareholder's shareholding in the company. From July 9, 2024 to July 16, 2024, the company's controlling shareholders Wang Weidong, Fang Jianmin, Lin Jian, Wang Liqiang, Wang Xudong, Deng Yong, Xiong Xiaobin, Yang Minhua, Wen Qingkai, Wei Jianliang, through their controlled enterprise Yantai Rongchang Holdings Group Co., Ltd., increased their holding of the company's shares by 0.18 million shares, accounting for 0.0331% of the total share capital of the company, with a total amount of RMB 5.109 million (excluding transaction fees) through the centralized bidding method on the Shanghai Stock Exchange system.
Remegen received a cumulative shareholding of 0.18 million shares from its controlling shareholder.
Remegen (688331.SH) announced that from July 9, 2024 to July 16, 2024, the company's actual controller Wang Weidong, Fang Jianmin, Lin Jian, Wang Liqiang, Wang Xudong, Deng Yong, Xiong Xiaobin, Yang Minhua, Wen Qingkai, and Wei Jianliang will increase their shareholding in the company by 0.18 million shares through their controlled enterprise Yantai Rongchang Holding Group Co., Ltd. via the Shanghai Stock Exchange's centralized bidding system.
Hong Kong stock market movement | Remegen (09995) now rises more than 3%. The progress of RC18's overseas expansion is slower than expected, but the National Medical Insurance Catalog can still ensure the growth of key product sales.
Zhixing Finance App learned that Remegen (09995) is now up more than 3%, as of press time, up 3.39%, at HKD 16.46, with a turnover of 17.8543 million HKD. In terms of news, on July 8th and 9th, Remegen's A-shares and H-shares respectively fell by 27% and 35%. Remegen announced that all its businesses are progressing normally, and its controlling shareholder intends to increase its shareholding by up to 20 million RMB. In addition, the company held a conference call to report on the progress of international cooperation for RC18, cash flow and overseas patent expirations to the market. CICC released a research report indicating that the market is concerned about the main
Hong Kong stocks fluctuate | Remegen (09995) falls by more than 3%, with slower progress than expected for RC18's overseas deployment, causing market concerns about the company's cash flow situation.
According to the Zhitong Finance APP, Remegen (09995) fell more than 3% and as of press time, it fell 3.17%, reported at HKD 15.88, with a turnover of HKD 16.0037 million. On the news front, a research report from Pu Yin International pointed out that on July 8th and 9th, Remegen A shares and H shares respectively fell by 27% and 35%, mainly due to the current fragile market sentiment, RC18's overseas progress is lower than expected, which increased investors' concerns about the company's cash flow situation. The management stated that RC18's overseas development still faces challenges, and various overseas methods will be considered in the future. The bank stated that considering the company's first phase of overseas projects, it remains on-track with preparations for the clinical study, preparing for the long-term growth of the biotechnology a industry, and maintaining its 'Hold' rating on Remegen's listed in Hong Kong shares.
[Brokerage Focus] CICC lowers the target price of Remegen (09995) by 11.76%, citing RC18 authorization issues as the biggest recent challenge.
Jingu Caixun | China International issued a research report, stating that from July 8th to 10th, Remegen (09995) accumulated a drop of more than 36%, and market concerns mainly focused on: 1) the overseas business development of the key drug RC18, namely the lack of success in global equity authorization and licensing; 2) whether the company can achieve its target of 50% year-on-year growth in total revenue set by the market; 3) the refinancing capability and credit line of Remegen. The bank believes that the authorization and licensing issue is the biggest challenge. The bank pointed out that the national medical insurance catalog provides a refuge for the sales growth of key products. Based on first-quarter revenue, it predicts its second quarter of 2024.
Hong Kong stock market anomaly | Remegen (09995) rose by more than 5% again. The company stated that all businesses are progressing normally, and the controlling shareholder intends to increase shareholding in the company.
According to the WiseNews app, Remegen (09995) has risen more than 5% again, although this week's cumulative decline has exceeded 23%. As of press time, it has risen 5.46% to HKD 16.62, with a turnover of HKD 49.4734 million. In terms of news, Remegen issued a notice of abnormal fluctuations in stock trading. According to market rumors, some of the company's products' external authorization progress did not meet expectations. After the company's self-inspection, all business operations are currently proceeding as usual, without involving hot market concepts. The company also responded that it has a certain amount of cash reserves; commercialization brings a certain scale of cash flow; has adequate bank credit; and potential international cooperation may also come.
No Data